Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

Bibliography

• MURRAY CJ, LOPEZ AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet (1997) 349:1269-1276.
   PubMed Web of Science ®Google Scholar
• EXPERT PANEL ON DETECTION,EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
   PubMed Web of Science ®Google Scholar
• KANNEL WB: Range of serum cholesterol values in the population developing coronary artery disease. Am. J. Cardiol. (1995) 76:69C-77C.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, SHEPHERD J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. (1997) 17:3542-3556.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, BRESLOW JL, HENNEKENS CH et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA (1988) 260:1917-1921.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, KING MC, VRANIZAN KM, KRAUSS RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation (1990) 82:495-506.
   PubMed Web of Science ®Google Scholar
• CAMPOS H, BLIJLEVENS E, MCNAMARA JR et al.: LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler. Thromb. (1992) 12:1410-1419.
   PubMed Web of Science ®Google Scholar
• SELBY JV, AUSTIN MA, NEWMAN B et al.: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation (1993) 88:381-387.
   PubMed Web of Science ®Google Scholar
• KRAUSS RM: Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. (2005) 25:2265-2272.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ: Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem. Soc. Trans. (2003) 31:1066-1069.
   PubMed Web of Science ®Google Scholar
• TAN KC, COOPER MB, LING KL et al.: Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis (1995) 113:273-287.
   PubMed Web of Science ®Google Scholar
• BERNEIS KK, KRAUSS RM: Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res. (2002) 43:1363-1379.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, CASLAKE M, SHEPHERD J: The role of small, dense low density lipoprotein (LDL): a new look. Int. J. Cardiol. (2000) 74(Suppl. 1):S17-S22.
   PubMed Web of Science ®Google Scholar
• GAZI I, LOURIDA ES, FILIPPATOS T et al.: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. (2005) 51:2264-2273.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, DEMANT T, STEWART JP et al.: Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid Res. (2000) 41:305-318.
   PubMed Web of Science ®Google Scholar
• BENTON JL, BLUMENTHAL RS, BECKER DM et al.: Predictors of low-density lipoprotein particle size in a high-risk African-American population. Am. J. Cardiol. (2005) 95:1320-1323.
   PubMed Web of Science ®Google Scholar
• RIZZO M, BERNEIS K: Should we measure routinely the LDL peak particle size? Int. J. Cardiol. (2006) 107:166-170.
   PubMed Web of Science ®Google Scholar
• KWITEROVICH PO: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am. J. Cardiol. (2002) 90:30i-47i.
   PubMed Web of Science ®Google Scholar
• SLYPER AH: Low-density lipoprotein density and atherosclerosis: unraveling the connection. JAMA (1994) 272:305-308.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA: Genetic control of low-density-lipoprotein subclasses. Lancet (1986) 2:592-595.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, TALMUD PJ, LUONG LA et al.: Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. Am. J. Hum. Genet. (1998) 62:406-419.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA: Genetic epidemiology of low-density lipoprotein subclass phenotypes. Ann. Med. (1992) 24:477-481.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA: Genetic and environmental influences on LDL subclass phenotypes. Clin. Genet. (1994) 46(1 Spec. No):64-70.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, BRUNZELL JD, FITCH WL, KRAUSS RM: Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis (1990) 10:520-530.
   PubMedGoogle Scholar
• AUSTIN MA, KRAUSS RM: LDL density and atherosclerosis. JAMA (1995) 273:115.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER Y, KARK JD, SINNREICH R, EDWARDS KL, AUSTIN MA: Inheritance of LDL peak particle diameter: results from a segregation analysis in Israeli families. Genet. Epidemiol. (1999) 16:382-396.
   PubMed Web of Science ®Google Scholar
• EDWARDS KL, MAHANEY MC, MOTULSKY AG, AUSTIN MA: Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2456-2464.
   PubMed Web of Science ®Google Scholar
• BOSSE Y, PERUSSE L, DESPRES JP et al.: Evidence for a major quantitative trait locus on chromosome 17q21 affecting low-density lipoprotein peak particle diameter. Circulation (2003) 107:2361-2368.
   PubMed Web of Science ®Google Scholar
• BOSSE Y, PERUSSE L, VOHL MC: Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations. J. Lipid Res. (2004) 45:1008-1026.
   PubMed Web of Science ®Google Scholar
• KRAUSS RM: Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu. Rev. Nutr. (2001) 21:283-295.
   PubMed Web of Science ®Google Scholar
• CZERWINSKI SA, MAHANEY MC, RAINWATER DL et al.: Gene by smoking interaction: evidence for effects on low-density lipoprotein size and plasma levels of triglyceride and high-density lipoprotein cholesterol. Hum. Biol. (2004) 76:863-876.
   PubMed Web of Science ®Google Scholar
• SHEARMAN AM, DEMISSIE S, CUPPLES LA et al.: Tobacco smoking, estrogen receptor a gene variation and small low density lipoprotein level. Hum. Mol. Genet. (2005) 14:2405-2413.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, RIZOS E, MIKHAILIDIS DP: Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology (2001) 52:575-587.
   PubMed Web of Science ®Google Scholar
• SIRI PW, KRAUSS RM: Influence of dietary carbohydrate and fat on LDL and HDL particle size. Curr. Atheroscler. Rep. (2005) 7:455-459.
   PubMedGoogle Scholar
• DREON DM, KRAUSS RM: Diet-gene interactions in human lipoprotein metabolism. J. Am. Coll. Nutr. (1997) 16:313-324.
   PubMed Web of Science ®Google Scholar
• LUC G, BARD JM, POULAIN P et al.: Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study. Eur. J. Clin. Invest. (1997) 27:242-247.
   PubMed Web of Science ®Google Scholar
• CARR MC, AYYOBI AF, MURDOCH SJ, DEEB SS, BRUNZELL JD: Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler. Thromb. Vasc. Biol. (2002) 22:667-673.
   PubMed Web of Science ®Google Scholar
• WANG J, QIANG H, CHEN D, ZHANG C, ZHUANG Y: CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Clin. Chim. Acta (2002) 322:85-90.
   PubMed Web of Science ®Google Scholar
• TALMUD PJ, EDWARDS KL, TURNER CM et al.: Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation (2000) 101:2461-2466.
   PubMed Web of Science ®Google Scholar
• SKOGLUND-ANDERSSON C, EHRENBORG E, FISHER RM et al.: Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men. Atherosclerosis (2003) 167:311-317.
   PubMed Web of Science ®Google Scholar
• HAVEL RJ: Genetic underpinnings of LDL size and density: a role for hepatic lipase? Am. J. Clin. Nutr. (2000) 71:1390-1391.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA T, KITAJIMA S, LIANG J et al.: Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Lab. Invest. (2004) 84:715-726.
   PubMed Web of Science ®Google Scholar
• ESTEVE E, FAURE E, CALVO F et al.: SNP3 polymorphism in apo A-V gene is associated with small dense LDL particles in Type 2 diabetes. Diabetologia (2004) 47:355-356.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, TALMUD PJ, FARIN FM et al.: Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim. Biophys. Acta (2004) 1688:1-9.
   PubMed Web of Science ®Google Scholar
• HOGUE JC, LAMARCHE B, GAUDET D et al.: Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial combined hypercholesterolemia. Atherosclerosis (2006) 184:163-170.
   PubMed Web of Science ®Google Scholar
• HIRANO T, ITO Y, YOSHINO G: Measurement of small dense low-density lipoprotein particles. J. Atheroscler. Thromb. (2005) 12:67-72.
   PubMed Web of Science ®Google Scholar
• OTVOS J: Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin. Cardiol. (1999) 22(6 Suppl.):II21-II27.
   PubMed Web of Science ®Google Scholar
• OTVOS JD, JEYARAJAH EJ, CROMWELL WC: Measurement issues related to lipoprotein heterogeneity. Am. J. Cardiol. (2002) 90(Suppl.):22i-29i.
   PubMed Web of Science ®Google Scholar
• NICHOLS AV, KRAUSS RM, MUSLINER TA: Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. (1986) 128:417-433.
   PubMed Web of Science ®Google Scholar
• HIRANO T, ITO Y, SAEGUSA H, YOSHINO G: A novel and simple method for quantification of small, dense LDL. J. Lipid Res. (2003) 44:2193-2201.
   PubMed Web of Science ®Google Scholar
• HIRANO T, ITO Y, KOBA S et al.: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler. Thromb. Vasc. Biol. (2004) 24:558-563.
   PubMed Web of Science ®Google Scholar
• HOEFNER DM, HODEL SD, O’BRIEN JF et al.: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin. Chem. (2001) 47:266-274.
   PubMed Web of Science ®Google Scholar
• WAGNER AM, JORBA D, RIGLA M et al.: LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype in Type 2 diabetes. Acta Diabetol. (2002) 39:215-220.
   PubMed Web of Science ®Google Scholar
• CAPELL WH, ZAMBON A, AUSTIN MA, BRUNZELL JD, HOKANSON JE: Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1040-1046.
   PubMed Web of Science ®Google Scholar
• SNIDERMAN AD: How, when, and why to use apolipoprotein B in clinical practice. Am. J. Cardiol. (2002) 90:48i-54i.
   PubMed Web of Science ®Google Scholar
• MARUYAMA C, IMAMURA K, TERAMOTO T: Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J. Atheroscler. Thromb. (2003) 10:186-191.
   PubMedGoogle Scholar
• NIELSEN LB: Transfer of low-density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis (1996) 123:1-15.
   PubMed Web of Science ®Google Scholar
• ANBER V, MILLAR JS, MCCONNEL M, SHEPHERD J, PACKARD CJ: Interaction of very low-density, intermediate-density and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2507-2514.
   PubMed Web of Science ®Google Scholar
• KRAUSS RM: Atherogenic lipoprotein phenotype and diet-gene interactions. J. Nutr. (2001) 131:340S-343S.
   PubMed Web of Science ®Google Scholar
• SATTAR N, PETRIE JR, JAAP AJ: The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis (1998) 138:229-235.
   PubMed Web of Science ®Google Scholar
• WOODMAN RJ, WATTS GF, PLAYFORD DA, BEST JD, CHAN DC: Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in Type 2 diabetes. Diabetes Obes. Metab. (2005) 7:612-617.
   PubMed Web of Science ®Google Scholar
• LUPATTELLI G, LOMBARDINI R, SCHILLACI G et al.: Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am. Heart J. (2000) 140:521-526.
   PubMed Web of Science ®Google Scholar
• NIGON F, LESNIC P, ROUIS M, CHAPMAN MJ: Discrete subspecies of human low-density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J. Lipid Res. (1991) 32:1741-1753.
   PubMed Web of Science ®Google Scholar
• GALEANO NF, MILNE R, MARCEL YL et al.: Apoprotein B structure and receptor recognition of triacylglyceride-rich low-density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J. Biol. Chem. (1994) 269:511-519.
   PubMed Web of Science ®Google Scholar
• GALEANO NF, AL HAISERI M, KEYSERMAN F, RUMSEY SC, DECKELBAUM RJ: Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid Res. (1998) 39:1263-1273.
   PubMed Web of Science ®Google Scholar
• TOYOTA Y, YAMAMURA T, MIYAKE Y, YAMAMOTO A: Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis (1999) 147:77-86.
   PubMed Web of Science ®Google Scholar
• RIZZO M, BERNEIS K: Low-density lipoprotein size and cardiovascular risk assessment. QJM (2006) 99:1-14.
   PubMed Web of Science ®Google Scholar
• MAKI KC, DAVIDSON MH, MARX P, CYROWSKI MS, MAKI A: Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am. J. Cardiol. (2000) 85:451-456.
   PubMed Web of Science ®Google Scholar
• KAKAFIKA AI, LIBEROPOULOS EN, MIKHAILIDIS DP: Fibrinogen: a predictor of vascular disease. Curr. Pharm. Des. (2006) (In Press).
   Google Scholar
• FESTA A, D’AGOSTINO R, MYKKANEN L et al.: Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler. Thromb. Vasc. Biol. (1999) 19:605-610.
   PubMed Web of Science ®Google Scholar
• LI J, KONDO A, MAEKEWA M, KANAMORI M, KANNO T: Hypertriglyceridemia characterized by low-density lipoprotein phenotype and lipoprotein lipase gene mutation. Clin. Chem. Lab. Med. (2000) 38:1263-1270.
   PubMed Web of Science ®Google Scholar
• HALLE M, BERG A, BAUMSTARK MW et al.: Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. Atherosclerosis (1999) 143:185-192.
   PubMed Web of Science ®Google Scholar
• HYSON D, RUTLEDGE JC, BERGLUND L: Postprandial lipemia and cardiovascular disease. Curr. Atheroscler. Rep. (2003) 5:437-444.
   PubMedGoogle Scholar
• ROCHE HM, GIBNEY MJ: The impact of postprandial lipemia in accelerating atherothrombosis. J. Cardiovasc. Risk (2000) 7:317-324.
   PubMedGoogle Scholar
• LEMIEUX I, COUILLARD C, PASCOT A et al.: The small, dense LDL phenotype as a correlate of postprandial lipemia in men. Atherosclerosis (2000) 153:423-432.
   PubMed Web of Science ®Google Scholar
• KARPE F, TORNVALL P, OLIVECRONA T et al.: Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis (1993) 98:33-49.
   PubMed Web of Science ®Google Scholar
• KOBA S, TSUNODA F, HIRANO T et al.: Postprandial changes in LDL phenotypes in patients with myocardial infarction. Eur. J. Clin. Invest. (2005) 35:171-179.
   PubMed Web of Science ®Google Scholar
• TSUNODA F, KOBA S, HIRANO T et al.: Association between small dense low-density lipoprotein and postprandial accumulation of triglyceride-rich remnant-like particles in normotriglyceridemic patients with myocardial infarction. Circ. J. (2004) 68:1165-1172.
   PubMed Web of Science ®Google Scholar
• KOLOVOU GD, ANAGNOSTOPOULOU KK, DASKALOPOULOU SS, MIKHAILIDIS DP, COKKINOS DV: Clinical relevance of postprandial lipaemia. Curr. Med. Chem. (2005) 12:1931-1945.
   PubMed Web of Science ®Google Scholar
• TAKAYANAGI N, ONUMA T, KATO S et al.: Association between LDL particle size and postprandial increase of remnant-like particles in Japanese Type 2 diabetic patients. Diabetes Res. Clin. Pract. (2004) 66:245-252.
   PubMed Web of Science ®Google Scholar
• BLACKBURN P, COTE M, LAMARCHE B et al.: Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size. Metabolism (2003) 52:1379-1386.
   PubMed Web of Science ®Google Scholar
• KARPE F: Postprandial lipemia-effect of lipid-lowering drugs. Atheroscler. Suppl. (2002) 3:41-46.
   PubMed Web of Science ®Google Scholar
• DASKALOVA DC, KOLOVOU GD, PANAGIOTAKOS DB, PILATIS ND, COKKINOS DV: Increase in aortic pulse wave velocity is associated with abnormal postprandial triglyceride response. Clin. Cardiol. (2005) 28:577-583.
   PubMedGoogle Scholar
• KOLOVOU GD, ANAGNOSTOPOULOU KK, PAVLIDIS AN et al.: Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis. (2005) 4:21.
   PubMedGoogle Scholar
• KOLOVOU GD, DASKALOVA DC, IRAKLIANOU SA et al.: Postprandial lipemia in hypertension. J. Am. Coll. Nutr. (2003) 22:80-87.
   PubMed Web of Science ®Google Scholar
• KOLOVOU GD, ANAGNOSTOPOULOU KK, SALPEA KD et al.: Postprandial lipemia in postmenopausal women with high fasting high-density lipoprotein cholesterol. Am. J. Med. Sci. (2006) 331:10-16.
   PubMed Web of Science ®Google Scholar
• KOLOVOU GD, ANAGNOSTOPOULOU KK, PILATIS ND et al.: Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post-prandially. Evidence for another predictor of vascular risk in familial hypercholesterolemia. Int. J. Clin. Pract. (2005) 59:311-317.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM: Lipoprotein disorders associated with Type 2 diabetes mellitus and insulin resistance. Am. J. Cardiol. (2002) 90:55i-61i.
   PubMed Web of Science ®Google Scholar
• VERGES B: Dyslipidaemia in diabetes mellitus. Diabetes Metab. (1999) 25(Suppl. 3):32-40.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352:837-853.
   PubMed Web of Science ®Google Scholar
• FROLICH J, STEINER G: Dyslipidaemia and coagulation defects of insulin resistance. Int. J. Clin. Pract. Suppl. (2000) 113:14-22.
   Google Scholar
• VERGES B: Diabetic dyslipidaemia:insights for optimizing patient management. Curr. Med. Res. Opin. (2005) 21(Suppl. 1):S29-S40.
   PubMed Web of Science ®Google Scholar
• KREISBERG RA: Diabetic dyslipidemia. Am. J. Cardiol. (1998) 82:67U-73U.
   PubMed Web of Science ®Google Scholar
• KOLOVOU GD, ANAGNOSTOPOULOU KK, COKKINOS DV: Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J. (2005) 81:358-366.
   PubMed Web of Science ®Google Scholar
• WATSON KE, HOROWITZ BN, MATSON G: Lipid abnormalities in insulin resistant states. Rev. Cardiovasc. Med. (2003) 4:228-236.
   PubMedGoogle Scholar
• KAKAFIKA AI, LIBEROPOULOS EN, KARAGIANNIS A, ATHYROS VG, MIKHAILIDIS DP: Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr. Vasc. Pharmacol. (2006) 4:175-183.
   PubMedGoogle Scholar
• SNIDERMAN AD, SCANTLEBURY T, CIANFLONE K: Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in Type 2 diabetes. Ann. Intern. Med. (2001) 135:447-459.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Multiple CHD risk factors in Type 2 diabetes: beyond hyperglycaemia. Diabetes Obes. Metab. (2002) 4(Suppl. 1):S13-S18.
   PubMed Web of Science ®Google Scholar
• WINDLER E: What is the consequence of an abnormal lipid profile in patients with Type 2 diabetes or the metabolic syndrome? Atherosclerosis Suppl. (2005) 6:11-14.
   PubMedGoogle Scholar
• KRAUSS RM: Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care (2004) 27:1496-1504.
   PubMed Web of Science ®Google Scholar
• GUERIN M, LE GOFF W, LASSEL TS et al.: Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in Type 2 diabetes: impact of degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. (2001) 21:282-288.
   PubMed Web of Science ®Google Scholar
• TASKINEN MR: Type 2 diabetes as a lipid disorder. Curr. Mol. Med. (2005) 5:297-208.
   Google Scholar
• HAFFNER SM, D’AGOSTINO R, MYKKANEN L et al.: Insulin sensitivity in subjects with NIDDM. Relationship to cardiovascular risk factors and carotid artery intima-media thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care (1999) 22:562-568.
   PubMed Web of Science ®Google Scholar
• FEINGOLD KR, GRUNFELD C, PANG M, DIERRLER W, KRAUSS RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. (1992) 12:1496-1502.
   PubMed Web of Science ®Google Scholar
• LEE W, MIN WK, CHUN S et al.: Low-density lipoprotein subclass and its correlating factors in diabetics. Clin. Biochem. (2003) 36:657-661.
   PubMed Web of Science ®Google Scholar
• TAN CE, CHEW LS, CHIO LF et al.: Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res. Clin. Pract. (2001) 51:107-114.
   PubMed Web of Science ®Google Scholar
• HOWARD BV, COWAN LD, GO O et al.: Adverse effects of diabetes on multiple cardiovascular disease risk factors in women: the Strong Heart Study. Diabetes Care (1998) 21:1258-1265.
   PubMed Web of Science ®Google Scholar
• SIEGEL RD, CUPPLES A, SCHAEFER EJ, WILSON PW: Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism (1996) 45:1267-1272.
   PubMed Web of Science ®Google Scholar
• TASKINEN MR: LDL-cholesterol, HDL-cholesterol or triglycerides- which is the culprit? Diabetes Res. Clin. Pract. (2003) 61:S19-S26.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, SELBY JV: LDL subclass phenotypes and the risk factors of the insulin resistance syndrome. Int. J. Obes. Relat. Metab. Disord. (1995) 19(Suppl. 1):S22-S26.
   PubMed Web of Science ®Google Scholar
• SLYPER AH, ZVEREVA S, SCHECTMAN G et al.: Insulin resistance is not a major determinant of low density lipoprotein particle size. Metabolism (1997) 46:1275-1280.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, CHEN YD, JEPPESEN J, MAHEUX P, KRAUSS RM: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. (1993) 92:141-146.
   PubMed Web of Science ®Google Scholar
• FESTA A, D’AGOSTINO R, MYKKANEN L et al.: LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care (1999) 22:1688-1693.
   PubMed Web of Science ®Google Scholar
• GOFF DC, D’AGOSTINO RB, HAFFNER SM, OTVOS JD: Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism (2005) 54:264-270.
   PubMed Web of Science ®Google Scholar
• FESTA A, WILLIAMS K, HANLEY AJ et al.: Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation (2005) 111:3465-3472.
   PubMed Web of Science ®Google Scholar
• GARVEY WT, KWON SW, ZHENG D et al.: Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes (2003) 52:453-462.
   PubMed Web of Science ®Google Scholar
• ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24:683-689.
   PubMed Web of Science ®Google Scholar
• ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus; the METS-GREECE Multicentre Study. METS-GREECE Collaborative Group. Curr. Med. Res. Opin. (2004) 20:1691-1701.
   PubMed Web of Science ®Google Scholar
• DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF M: Prevention and treatment of the metabolic syndrome. Angiology (2004) 55:589-612.
   PubMed Web of Science ®Google Scholar
• LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF MS: Diagnosis and management of metabolic syndrome in obesity. Obes. Rev. (2005) 6:283-296.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, DESROCHES S: Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience. Am. J. Clin. Nutr. (2004) 79:1149S-1152S.
   PubMed Web of Science ®Google Scholar
• HULTHE J, BOKEMARK L, WIKSTRAND J, FAGERBERG B: The metabolic syndrome, LDL particle size and atherosclerosis: The Atherosclerosis and Insulin Resistance Study. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2140-2147.
   PubMed Web of Science ®Google Scholar
• FAGERBERG B, HULTHE J, BOKEMARK L, WIKSTRAND J: Low-density lipoprotein particle size, insulin resistance, and proinsulin in a population sample of 58-year old men. Metabolism (2001) 50:120-124.
   PubMed Web of Science ®Google Scholar
• MYKKANEN L, HAFFNER SM, RAINWATER DL et al.: Relationship of LDL size to insulin sensitivity in normoglycemic men. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1447-1453.
   PubMed Web of Science ®Google Scholar
• SIGURDARDOTTIR V, FAGERBERG B, HULTHE J: Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically health 58-year-old men (AIR study). J. Intern. Med. (2002) 252:440-447.
   Google Scholar
• GAZI I, TSIMIHODIMOS V, FILIPPATOS T et al.: Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 55:885-891.
   PubMed Web of Science ®Google Scholar
• DASKALOPOULOU SS, ATHYROS VG, KOLOVOU GD, ANAGNOSTOPOULOU KK, MIKHAILIDIS DP: Definitions of metabolic syndrome: where are we now? Curr. Vasc. Pharmacol. (2006) 4:185-197.
   PubMedGoogle Scholar
• GAZI I, LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF M: Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc. Dis. Prevent. (2004) 1:243-253.
   Google Scholar
• PIRWANY IR, FLEMING R, GRER IA, PACKARD CJ, SATTAR N: Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin. Endocrinol. (Oxford) (2001) 54:447-453.
   PubMed Web of Science ®Google Scholar
• TOLEDO FG, SNIDERMAN AD, KELLEY DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in Type 2 diabetes. Diabetes Care (2006) 29:1845-1850.
   PubMed Web of Science ®Google Scholar
• VAKKILAINEN J, JAUHIAINEN M, YLITALO K et al.: LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J. Lipid Res. (2002) 43:598-603.
   PubMed Web of Science ®Google Scholar
• HOKANSON JE, KRAUSS RM, ALBERS JJ, AUSTIN MA, BRUNZELL JD: LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. (1995) 15:452-459.
   PubMed Web of Science ®Google Scholar
• AYYOBI AF, MCGLADDERY SH, MCNEELY MJ et al.: Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1289-1294.
   PubMed Web of Science ®Google Scholar
• HOKANSON JE, AUSTIN MA, ZAMBON A, BRUNZELL JD: Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler. Thromb. (1993) 13:427-434.
   PubMedGoogle Scholar
• GEORGIEVA AM, VAN GREEVENBROEK MM, KRAUSS RM et al.: Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler. Thromb. Vasc. Biol. (2004) 24:744-749.
   PubMed Web of Science ®Google Scholar
• MILLER WM, NORI-JANOSZ KE, LILLYSTONE M, YANEZ J, MCCULLOUGH PA: Obesity and lipids. Curr. Cardiol. Rep. (2005) 7:465-470.
   PubMedGoogle Scholar
• KANG HS, GUTIN B, BARBEAU P et al.: Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths. Int. J. Obes. Relat. Metab. Disord. (2002) 26:1030-1035.
   PubMed Web of Science ®Google Scholar
• GAZI IF, FILIPPATOS TD, TSIMIHODIMOS V et al.: The hypertriglyceridaemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 41:647-654.
   PubMed Web of Science ®Google Scholar
• CARR MC, HOKANSON JE, ZAMBON A et al.: The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high lipoprotein heterogeneity. J. Clin. Endocrinol. Metab. (2001) 86:2831-2837.
   PubMed Web of Science ®Google Scholar
• BIOLETTO S, GOLAY A, MUNGER R, KALIX B, JAMES RW: Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects. Am. J. Clin. Nutr. (2000) 71:443-449.
   PubMed Web of Science ®Google Scholar
• LAMONTE MJ, AINSWORTH BE, DUBOSE KD et al.: The hypertriglyceridemic waist phenotype among women. Atherosclerosis (2003) 171:123-130.
   PubMed Web of Science ®Google Scholar
• LEMIEUX I, PASCOT A, COUILLARD C et al.: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation (2000) 102:179-184.
   PubMed Web of Science ®Google Scholar
• HULTHE J, HULTEN LM, FAGERBERG B: Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism (2003) 52:1612-1614.
   PubMed Web of Science ®Google Scholar
• DEIGHAN CJ, CASLAKE MJ, MCCONNELL JP, BOULTON-JONES JM, PACKARD CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am. J. Kidney Dis. (2000) 35:852-862.
   PubMed Web of Science ®Google Scholar
• PRICHARD SS: Impact of dyslipidemia in end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14:S315-S320.
   PubMed Web of Science ®Google Scholar
• WANNER C, QUASCHNING T: Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr. Opin. Nephrol. Hypertens. (2001) 10:195-201.
   PubMed Web of Science ®Google Scholar
• WANNER C, KRANE V: Uremia-specific alterations in lipid metabolism. Blood Purif. (2002) 20:451-453.
   PubMed Web of Science ®Google Scholar
• QUASCHNING T, KRANE V, METZGER T, WANNER C: Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am. J. Kidney Dis. (2001) 38(4 Suppl. 1):S14-S19.
   PubMed Web of Science ®Google Scholar
• OI K, HIRANO T, SAKAI K, KAWAGUCHI Y, HOSOYA T: Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int. Suppl. (1999) 71:S227-S228.
   PubMedGoogle Scholar
• BELANI SS, GOLDBERG AC, COYNE DW: Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients. Am. J. Kidney Dis. (2004) 43:320-329.
   PubMed Web of Science ®Google Scholar
• DEIGHAN CJ, CASLAKE MJ, MCCONNELL JP, BOULTON-JONES JM, PACKARD CJ: The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic proteinuria. Atherosclerosis (2001) 157:211-220.
   PubMed Web of Science ®Google Scholar
• KARABINA SA, PAPPAS H, MILTIADOUS G et al.: Compositional lipoprotein changes and low-density lipoprotein susceptibility to oxidation in chronic renal failure patients with heavy proteinuria. Nephron Clin. Pract. (2003) 95:c77-c83.
   PubMed Web of Science ®Google Scholar
• HURT-CAMEJO E, PAREDES S, MASANA L et al.: Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to its atherogenic profile. Arthritis Rheum. (2001) 44:2761-2767.
   PubMed Web of Science ®Google Scholar
• NUTTALL SL, HEATON S, PIPER MK, MARTIN U, GORDON C: Cardiovascular risk in systemic lupus erythematosus-evidence of increased oxidative stress and dyslipidaemia. Rheumatology (2003) 42:758-762.
   PubMed Web of Science ®Google Scholar
• MIWA K: Low density lipoprotein particles are small in patients with coronary vasospasm. Int. J. Cardiol. (2003) 87:193-201.
   PubMed Web of Science ®Google Scholar
• SIBLEY SD, HOKANSON JE, STEFFES MW et al.: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in Type 1 diabetes. Diabetes Care (1999) 22:1165-1170.
   PubMed Web of Science ®Google Scholar
• TAN KC, SHIU SW, JANUS ED, LAM KS: LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-1. Atherosclerosis (1997) 129:59-65.
   PubMed Web of Science ®Google Scholar
• AROSIO M, SARTORE G, ROSSI CM et al.: LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis (2000) 151:551-557.
   PubMed Web of Science ®Google Scholar
• KARMENA R, DURIEZ P, FRUCHART JC: Atherogenic lipoprotein particles in atherosclerosis. Circulation (2004) 109:III2-III7.
   PubMedGoogle Scholar
• CAMPOS H, GENEST JJ, BLIJLEVENS E et al.: Low density lipoprotein particle size and coronary artery disease. Arterioscler. Thromb. (1992) 12:187-195.
   PubMed Web of Science ®Google Scholar
• CORESH J, KWITEROVICH PJ, SMITH H, BACHORIK P: Association of plasma triglyceride concentration and LDL diameter density, and chemical composition with premature coronary artery disease in men and women. J. Lipid Res. (1993) 34:1687-1697.
   PubMed Web of Science ®Google Scholar
• TORNVALL P, KARPE F, CARLSON LA, HAMSTEN A: Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis (1991) 90:67-80.
   PubMed Web of Science ®Google Scholar
• KOBA S, HIRANO T, KONDO T et al.: Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am. Heart J. (2002) 144:1026-1035.
   PubMed Web of Science ®Google Scholar
• YOON Y, SONG J, PARK HD, K.U. P, KIM JQ: Significance of small dense low-density lipoproteins as coronary risk factor in diabetic and non-diabetic Korean populations. Clin. Chem. Lab. Med. (2005) 43:431-437.
   Web of Science ®Google Scholar
• GARDNER CD, FORMANN SP, KRAUSS RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA (1996) 276:875-881.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, TCHERNOF A, MOORJANI S et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation (1997) 95:69-75.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, KRAUSS RM, MA J et al.: A prospective study of triglyceride levels, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 276:882-888.
   PubMed Web of Science ®Google Scholar
• AUSTIN MA, RODRIGUEZ BL, MCKNIGHT B et al.: Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am. J. Cardiol. (2000) 86:412-416.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, TCHERNOF A, MAURIEGE P et al.: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA (1998) 279:1955-1961.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE AC, CANTIN B, DAGENAIS GR et al.: Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation (2001) 104:2295-2299.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE AC, CANTIN B, DAGENAIS GR et al.: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men:13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. (2005) 25:553-559.
   Google Scholar
• ST-PIERRE AC, BERGERON J, PIRRO M et al.: Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoprotein in men (the Quebec Cardiovascular Study). Am. J. Cardiol. (2003) 91:555-558.
   PubMed Web of Science ®Google Scholar
• KOBA S, HIRANO T, ITO Y et al.: Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis (2006) 189:206-214.
   PubMed Web of Science ®Google Scholar
• KOBA S, HIRANO T, YOSHINO G et al.: Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis (2002) 160:249-256.
   PubMed Web of Science ®Google Scholar
• KULLO IJ, BAILEY KR, MCCONNELL JP et al.: Low-density lipoprotein particle size and coronary atherosclerosis in subjects belonging to hypertensive sibships. Am. J. Hypertens. (2004) 17:845-851.
   PubMed Web of Science ®Google Scholar
• MYKKANEN L, KUUSISTO J, HAFFNER SM, LAAKSO M, AUSTIN MA: LDL size and risk of coronary heart disease in elderly men and women. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2742-2748.
   PubMed Web of Science ®Google Scholar
• KAMIGAKI AS, SISCOVICK DS, SCHWARTZ SM et al.: Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am. J. Epidemiol. (2001) 153:939-945.
   PubMed Web of Science ®Google Scholar
• KWON SW, YOON SJ, KANG TS et al.: Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med. J. (2006) 47:405-414.
   PubMed Web of Science ®Google Scholar
• BERNEIS KK, JEANNERET C, MUSER J, FELIX B, MISEREZ AR: Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type 2 diabetes. Metabolism (2005) 54:227-234.
   PubMed Web of Science ®Google Scholar
• JUNGNER I, SNIDERMAN AD, FURBERG C et al.: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am. J. Cardiol. (2006) 97:943-946.
   PubMed Web of Science ®Google Scholar
• SNIDERMAN AD, LAMARCHE B, TILLEY J, SECCOMBE D, FROLICH J: Hypertriglyceridemic hyperapoB in Type 2 diabetes. Diabetes Care (2002) 25:579-582.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, MOORJANI S, LUPIEN PJ et al.: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation (1996) 94:273-278.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE AC, CANTIN B, DAGENAIS GR, DESPRES JP, LAMARCHE B: Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am. J. Cardiol. (2006) 97:997-1001.
   PubMed Web of Science ®Google Scholar
• BARTER PJ, BALLANTYNE CM, CARMENA R et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. (2006) 259:247-258.
   Google Scholar
• KULLER L, ARNOLD A, TRACY R et al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1175-1180.
   PubMed Web of Science ®Google Scholar
• OEI HH, VAN DER MEER IM, HOFMAN A et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. Circulation (2005) 111:570-575.
   PubMed Web of Science ®Google Scholar
• TSELEPIS AD, DENTAN C, KARABINA SA, CHAPMAN MJ, NINIO E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzymes. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1764-1773.
   PubMed Web of Science ®Google Scholar
• TSELEPIS AD, CHAPMAN MJ: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Atheroscler Suppl. (2002) 3:57-68.
   PubMed Web of Science ®Google Scholar
• KARABINA SA, LIAPIKOS TA, GREKAS G, GOUDEVENOS J, TSELEPIS AD: Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim. Biophys. Acta (1994) 1213:34-38.
   PubMed Web of Science ®Google Scholar
• KARABINA SA, ELISAF M, BAIRAKTARI E et al.: Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. (1997) 27:595-602.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, KARABINA SA, TAMBAKI AP et al.: Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. (2002) 43:256-263.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, KARABINA SA, TAMBAKI AP et al.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemia of Type IIA and Type IIB. Arterioscler. Thromb. Vasc. Biol. (2002) 22:306-311.
   PubMed Web of Science ®Google Scholar
• O’DONOGHUE M, MORROW DA, SABATINE MS et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22(Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation (2006) 113:1745-1752.
   PubMed Web of Science ®Google Scholar
• IRIBARREN C, GROSS MD, DARBINIAN JA et al.: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults. The CARDIA study. Arterioscler. Thromb. Vasc. Biol. (2005) 25:216-221.
   PubMed Web of Science ®Google Scholar
• WINKLER K, WINKELMANN BR, SCHARNAGL H et al.: Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation (2005) 111:980-987.
   PubMed Web of Science ®Google Scholar
• CAMPOS H, ROEDERER GO, LUSSIER-CACAN S, DAVIGNON J, KRAUSS RM: Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1043-1048.
   PubMed Web of Science ®Google Scholar
• GRAY RS, ROBBINS DC, WANG W et al.: Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians, the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2713-2720.
   PubMed Web of Science ®Google Scholar
• CAMPOS H, MOYE LA, GLASSER SP, STAMPFER SP, SACKS FM: Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA (2001) 286:1468-1474.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, RIZOS E, GOUDEVENOS J et al.: Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 36:1372-1376.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, LIBEROPOULOS EN, GOUDEVENOS J et al.: Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int. J. Cardiol. (2005) 99:269-275.
   PubMed Web of Science ®Google Scholar
• RIZZO M, BERNEIS K: The role of small, dense low-density-lipoproteins in non-coronary forms of atherosclerosis. Vasc. Dis. Prevent. (2006) 3:269-274.
   Google Scholar
• SKOGLUND-ANDERSSON C, TANG R, BOND MG et al.: LDL particle size distribution is associated with carotid intima media thickness in healthy 50-year-old men. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2422-2430.
   PubMed Web of Science ®Google Scholar
• HALLMAN DM, BROWN SA, BALLANTYNE CM, SHARRETT AR, BOERWINKLE E: Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. Biomarkers (2004) 9:190-202.
   PubMed Web of Science ®Google Scholar
• VAN TITS LJ, SMILDE TJ, VAN WISSEN S et al.: Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J. Invest. Med. (2004) 52:177-184.
   Google Scholar
• LIU ML, YLITALO K, NUOTIO I et al.: Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke (2002) 33:1255-1260.
   PubMed Web of Science ®Google Scholar
• WATANABE T, KOBA S, KAWAMURA M et al.: Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism (2004) 53:476-482.
   PubMed Web of Science ®Google Scholar
• O’NEAL DN, LEWICKI J, ANSARI MZ, MATTHEWS PG, BEST JD: Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects. Atherosclerosis (1998) 136:1-8.
   PubMed Web of Science ®Google Scholar
• LUPATTELLI G, PASQUALINI L, SIEPI D et al.: Increased postprandial lipemia in patients with normolipemic peripheral arterial disease. Am. Heart J. (2002) 143:733-738.
   PubMed Web of Science ®Google Scholar
• RIZZO M, BERNEIS K: The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc. Drugs Ther. (2006) 20:205-217.
   PubMed Web of Science ®Google Scholar
• HOOGERBRUGGE N, JANSEN H: Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis (1999) 146:167-174.
   PubMed Web of Science ®Google Scholar
• NORDOY A, HANSEN JB, BROX J, SVENSSON B: Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr. Metab. Cardiovasc. Dis. (2001) 11:7-16.
   Web of Science ®Google Scholar
• FREED MI, RATNER R, MARCOVINA SM et al.: Effect of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. On behalf of the Rosiglitazone Study 108 investigators. Am. J. Cardiol. (2002) 90:947-952.
   PubMed Web of Science ®Google Scholar
• PONTRELLI L, PARRIS W, ADLI K, CHEUNG RC: Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism (2002) 51:334-342.
   PubMed Web of Science ®Google Scholar
• SAKABE K, FUKUDA N, WAKAYAMA K et al.: Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circ. J. (2003) 67:866-870.
   Web of Science ®Google Scholar
• LARIVIERE M, LAMARCHE B, PIRRO M et al.: Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Atherosclerosis (2003) 167:97-104.
   PubMed Web of Science ®Google Scholar
• LINS RL, MATTHYS KE, BILLIOUW JM et al.: Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin. Nephrol. (2004) 62:287-294.
   PubMed Web of Science ®Google Scholar
• BALDASSARRE S, SERUEL O, DECKELBAUM RJ et al.: Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Int. J. Cardiol. (2005) 104:338-345.
   PubMed Web of Science ®Google Scholar
• EMPEN K, GEISS HC, LEHRKE M et al.: Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. Nutr. Metab. Cardiovasc. Dis. (2003) 13:87-92.
   Web of Science ®Google Scholar
• MCKENNEY JM, MCCORMICK LS, SCHAEFER EJ, BLACK DM, WATKINS ML: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol. (2001) 88:270-274.
   PubMed Web of Science ®Google Scholar
• O’KEEFE JH, CAPTAIN BK, JONES PG, HARRIS WS: Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev. Cardiol. (2004) 7:154-160.
   PubMedGoogle Scholar
• SASAKI S, KUWAHARA N, KUNITOMO K et al.: Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol. (2002) 89:386-389.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR, CALABRESI L, PISCIOTTA L et al.: Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr. Metab. Cardiovasc. Dis. (2005) 15:47-55.
   PubMed Web of Science ®Google Scholar
• GUERIN M, EGGER P, SOUDANT C et al.: Dose-dependent action of atorvastatin in Type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis (2002) 163:287-296.
   PubMed Web of Science ®Google Scholar
• GEISS HC, OTTO C, SCHWANDT P, PARHOFER KG: Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism (2001) 50:983-988.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, KARABINA SA, TAMBAKI A et al.: Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of Type IIA and IIB. J. Cardiovasc. Pharmacol. (2003) 42:304-310.
   PubMed Web of Science ®Google Scholar
• DORNBROOK-LAVENDER KA, JOY MS, DENU-CIOCCA CJ et al.: Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy (2005) 25:335-344.
   PubMed Web of Science ®Google Scholar
• FROST RJ, OTTO C, GEISS HC, SCHWANDT P, PARHOFER KG: Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in Type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. (2001) 87:44-48.
   PubMed Web of Science ®Google Scholar
• GAW A, PACKARD CJ, MURRAY EF et al.: Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler. Thromb. (1993) 13:170-189.
   PubMedGoogle Scholar
• DE GRAAF J, DEMACKER PN, STALENHOEF AF: The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolemia. Neth. J. Med. (1993) 43:254-261.
   PubMed Web of Science ®Google Scholar
• BREDIE SJ, DE BRUIN TW, DEMACKER PN, KASTELEIN JJ, STALENHOEF AF: Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am. J. Cardiol. (1995) 75:348-353.
   PubMed Web of Science ®Google Scholar
• HOMMA Y, OZAWA H, KOBAYASHI T et al.: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in Type II hyperlipoproteinemia. Atherosclerosis (1995) 114:223-234.
   PubMed Web of Science ®Google Scholar
• HOOGERBRUGGE N, JANSEN H, DE HEIDE L et al.: The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. J. Intern. Med. (1998) 243:151-156.
   Google Scholar
• LAGROST L, ATHIAS A, LEMORT N et al.: Plasma lipoprotein distribution and lipid transfer activities in patients with Type IIb hyperlipidemia treated with simvastatin. Atherosclerosis (1999) 143:415-425.
   PubMed Web of Science ®Google Scholar
• BAYS HE, MCGOVERN ME: Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution that atorvastatin and simvastatin. Prev. Cardiol. (2003) 6:179-188.
   PubMedGoogle Scholar
• GEISS HC, SCHWANDT P, PARHOFER KG: Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp. Clin. Endocrinol. Diabetes (2002) 110:182-187.
   PubMed Web of Science ®Google Scholar
• VAN DER AKKER JM, BREDIE SJ, DIEPENVEEN SH et al.: Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J. Nephrol. (2003) 16:238-244.
   PubMed Web of Science ®Google Scholar
• KONTOPOULOS AG, ATHYROS VG, PAPAGEORGIOU AA et al.: Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron. Artery Dis. (1996) 7:843-850.
   PubMed Web of Science ®Google Scholar
• NESTEL P, SIMONS L, BARTER P et al.: A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apoE genotype, lipoprotein (a) and insulin. Atherosclerosis (1997) 129:231-239.
   PubMed Web of Science ®Google Scholar
• RIZZO M, BARBAGALLO CM, PERNICE V et al.: Simvastatin reduces the levels of apo E-containing triglyceride-rich lipoproteins in men with premature coronary artery disease. Atheroscler Suppl. (2002) 12:194 (Abstract).
   Google Scholar
• ZHAO SP, HOLLAAR L, VAN’T HOOFT FM et al.: Effect of simvastatin on the apparent size of LDL particles in patients with Type IIB hyperlipoproteinemia. Clin. Chim. Acta (1991) 16:109-117.
   Google Scholar
• MILLER M, DOBS A, YUAN Z, BATTISTI WP, PALMISANO J: The effect of simvastatin on triglyceride-rich lipoproteins in patients with Type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr. Med. Res. Opin. (2006) 22:343-350.
   PubMed Web of Science ®Google Scholar
• ZAMBON S, CORTELLA A, SARTORE G et al.: Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur. J. Clin. Pharmacol. (1994) 46:221-224.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, CASSINOTTI M, VECCHIO G et al.: Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler. Thromb. (1994) 14:1569-1575.
   PubMedGoogle Scholar
• BLAKE GJ, ALBERT MA, RIFAI N, RIDKER PM: Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. Eur. Heart J. (2003) 24:1843-1847.
   PubMed Web of Science ®Google Scholar
• CHEUNG MC, AUSTIN MA, MOULIN P et al.: Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis (1993) 102:107-119.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS, OTVOS JD, FREEDMAN DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary arteries (PLAC-I) trial. Am. J. Cardiol. (2002) 90:89-94.
   PubMed Web of Science ®Google Scholar
• OTVOS JD, SHALAUROVA I, FREEDMAN DS, ROSENSON RS: Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis (2002) 160:41-48.
   PubMed Web of Science ®Google Scholar
• YUAN JN, TSAI MY, HEGLAND J, HUNNINGHAKE DB: Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis (1991) 87:147-157.
   PubMed Web of Science ®Google Scholar
• MARZ W, SCHARNAGL H, ABLETSHAUSER C et al.: Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation (2001) 103:1942-1948.
   PubMed Web of Science ®Google Scholar
• YOSHINO G, HIRANO T, KAZUMI T, TAKEMOTO M, OHASHI N: Fluvastatin increases LDL particle size and educes oxidative stress in patients with hyperlipidemia. J. Atheroscler. Thromb. (2003) 10:343-347.
   PubMedGoogle Scholar
• SHIMABUKURO M, HIGA N, ASAHI T, OSHIRO Y, TAKASU N: Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction. Metabolism (2004) 53:733-739.
   PubMed Web of Science ®Google Scholar
• WINKLER K, ABLETSHAUSER C, HOFFMANN MM et al.: Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. (2002) 87:5485-5490.
   Google Scholar
• SUPERKO HR, KRAUSS RM, DIRICCO C: Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am. J. Cardiol. (1997) 80:78-81.
   PubMed Web of Science ®Google Scholar
• BEVILACQUA M, RIGHINI V, BARRELLA M et al.: Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with Type 2 diabetes. Adv. Ther. (2005) 22:527-542.
   PubMed Web of Science ®Google Scholar
• CASLAKE MJ, STEWART G, DAY SP et al.: Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis (2003) 171:245-253.
   PubMed Web of Science ®Google Scholar
• ELISAF M, TSELEPIS AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase.Implication for atherosclerosis. Biochem. Pharmacol. (2003) 66:2069-2073.
   PubMed Web of Science ®Google Scholar
• TAMBAKI AP, RIZOS E, TSIMIHODIMOS V, TSELEPIS AD, ELISAF M: Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J. Cardiovasc. Pharmacol. Ther. (2004) 9:91-95.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, MILTIADOUS G, DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF MS: Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. (2005) 3:87-98.
   PubMedGoogle Scholar
• DESPRES JP, LEMIEUX I, ROBINS SJ: Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs (2004) 64:2177-2198.
   PubMed Web of Science ®Google Scholar
• YUAN J, TSAI MY, HUNNINGHAKE DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis (1994) 110:1-11.
   PubMed Web of Science ®Google Scholar
• SUPERKO HR, BERNEIS KK, WILLIAMS PT, RIZZO M, WOOD PD: Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am. J. Cardiol. (2005) 96:1266-1272.
   PubMed Web of Science ®Google Scholar
• OTVOS JD, COLLINS D, FREEDMAN DS et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-density lipoprotein Intervention Trial. Circulation (2006) 113:1556-1563.
   PubMed Web of Science ®Google Scholar
• IKEWAKI K, TOHYAMA J, NAKATA Y et al.: Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J. Atheroscler. Thromb. (2004) 11:278-285.
   PubMedGoogle Scholar
• BADIOU S, MERLE DE BOEVER C, DUPUY AM et al.: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 172:273-279.
   PubMed Web of Science ®Google Scholar
• DEIGHAN CJ, CASLAKE MJ, MCCONNELL M, BOULTON-JONES JM, PACKARD CJ: Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J. Am. Soc. Nephrol. (2001) 12:341-348.
   PubMed Web of Science ®Google Scholar
• LEMIEUX I, LAPERRIERE L, DZAVIK V et al.: A 16-week fenofibrate treatment increases LDL particle size in Type IIA dyslipidemic patients. Atherosclerosis (2002) 162:363-371.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MJ, BAYS HE, STEIN E et al.: Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. TRIMS Investigators. Clin. Cardiol. (2006) 29:268-273.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, KAKAFIKA A, TAMBAKI AP et al.: Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res. (2003) 44:927-934.
   PubMed Web of Science ®Google Scholar
• FILIPPATOS TD, GAZI IF, LIBEROPOULOS EN et al.: The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis (2006) (In Press).
   Google Scholar
• KEECH A, SIMES RJ, BARTER P et al.: FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 366:1849-1861.
   PubMed Web of Science ®Google Scholar
• RIZOS E, MIKHAILIDIS DP: Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int. J. Cardiol. (2002) 82:199-207.
   PubMed Web of Science ®Google Scholar
• RUOTOLO G, ERICSSON CG, TETTAMANTI C et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low-density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol. (1998) 32:1648-1656.
   PubMed Web of Science ®Google Scholar
• IKEWAKI K, NOMA K, TOHYAMA J, KIDO T, MOCHIZUKI S: Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia- a nuclear magnetic resonance study. Int. J. Cardiol. (2005) 101:441-447.
   PubMed Web of Science ®Google Scholar
• GUERIN M, LE GOFF W, FRISDAL E et al.: Action of ciprofibrate in Type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J. Clin. Endocrinol. Metab. (2003) 88:3738-3746.
   Google Scholar
• WIERZBICKI AS, MIKHAILIDIS DP, WRAY R et al.: Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin. (2003) 19:155-168.
   PubMed Web of Science ®Google Scholar
• BRUNZELL JD, AYYOBI AF: Dyslipidemia in the metabolic syndrome and Type 2 diabetes mellitus. Am. J. Med. (2003) 115(Suppl. 8A):24S-28S.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
   PubMed Web of Science ®Google Scholar
• MORGAN JM, CAPUZZI DM, BAKSH RI et al.: Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. (2003) 91:1432-1436.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, VEGA GL, MCGOVERN ME et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Diabetes Multicenter Research Group. Arch. Intern. Med. (2002) 162:1568-1576.
   PubMed Web of Science ®Google Scholar
• MIKHAILIDIS DP, WIERZBICKI AS, DASKALOPOULOU SS et al.: The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr. Med. Res. Opin. (2005) 21:959-969.
   PubMed Web of Science ®Google Scholar
• AL-SHAER MH: The effects of ezetimibe on the LDL-cholesterol particle number. Cardiovasc. Drugs Ther. (2004) 18:327-328.
   PubMed Web of Science ®Google Scholar
• GEISS HC, OTTO C, PARHOFER KG: Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism (2006) 55:599-604.
   PubMed Web of Science ®Google Scholar
• GRIFFIN BA: The effect of n-3 fatty acids on low density lipoprotein subfractions. Lipids (2001) 36(Suppl.):S91-S97.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, DONATI D, PAZZUCCONI F, SIRTORI CR, FRANCESCHINI G: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis (2000) 148:387-396.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350:1505-1515.
   PubMed Web of Science ®Google Scholar
• SAIKI A, OHIRA M, ENDO K et al.: The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in Type 2 diabetes with hypertension. Diabetes Res. Clin. Pract. (2006) 74(3):242-248.
   PubMed Web of Science ®Google Scholar
• HIRANO T, YOSHINO G, KASHIWAZAKI K, ADACHI M: Doxazosin reduces prevalence of small dense low-density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am. J. Hypertens. (2001) 14:908-913.
   PubMed Web of Science ®Google Scholar
• WESTMAN EC, YANCY WS, OLSEN MK, DUDLEY T, GUYTON JR: Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int. J. Cardiol. (2006) 110:212-216.
   PubMed Web of Science ®Google Scholar
• LOFGREN I, ZERN T, HERRON K et al.: Weight loss associated with reduced intake of carbohydrate reduces the atherogenicity of LDL in premenopausal women. Metabolism (2005) 54:1133-1141.
   PubMed Web of Science ®Google Scholar
• MORENO JA, PEREZ-JIMENEZ F, MARIN C et al.: The effect of dietary fat on LDL size is influenced by apolipoprotein E genotype in healthy subjects. J. Nutr. (2004) 134:2517-2522.
   PubMed Web of Science ®Google Scholar
• WOOD RJ, VOLEK JS, LIU Y et al.: Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. J. Nutr. (2006) 136:384-389.
   PubMed Web of Science ®Google Scholar
• CHAREST A, DESROCHES S, VANSTONE CA, JONES PJ, LAMARCHE B: Unesterified plant sterols and stanols do not affect LDL electrophoretic characteristics in hypercholesterolemic subjects. J. Nutr. (2004) 134:592-595.
   PubMed Web of Science ®Google Scholar
• VARADY KA, ST-PIERRE AC, LAMARCHE B, JONES PJ: Effect of plant sterols and endurance training on LDL particle size and distribution in previously sedentary hypercholesterolemic adults. Eur. J. Clin. Nutr. (2005) 59:518-525.
   PubMed Web of Science ®Google Scholar
• CHAREST A, VANSTONE C, ST-ONGE MP, PARSON W, JONES PJ, LAMARCHE B: Phytosterols in nonfat and low-fat beverages have no impact on the LDL size phenotype. Eur. J. Clin. Nutr. (2005) 59:801-804.
   PubMed Web of Science ®Google Scholar
• GOULET J, LAMARCHE B, CHAREST A et al.: Effect of a nutritional intervention promoting the Mediterranean food pattern on electrophoretic characteristics of low-density lipoprotein particles in healthy women from the Quebec City metropolitan area. Br. J. Nutr. (2004) 92:285-293.
   PubMed Web of Science ®Google Scholar
• VERGES B: Clinical interest of PPARs ligands. Diabetes Metab. (2004) 30:7-12.
   PubMed Web of Science ®Google Scholar
• CAMEJO G: PPAR agonists in the treatment of insulin resistance and associated arterial disease. Int. J. Clin. Pract. Suppl. (2003) 134:36-44.
   Google Scholar
• PARULKAR AA, PENDERGRASS ML, GRANDA-AYALA R, LEE TR, FONSECA VA: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. (2001) 134:61-71.
   PubMed Web of Science ®Google Scholar
• CAMPBELL IW: The clinical significance of PPAR gamma agonism. Curr. Mol. Med. (2005) 5:349-363.
   Google Scholar
• SHEPHERD J, BETTERIDGE J, VAN GAAL L: Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by A European Consensus Panel. Curr. Med. Res. Opin. (2005) 21:665-682.
   PubMed Web of Science ®Google Scholar
• PARHOFER KG, OTTO C, GEISS HC, LAUBACH E, GOKE B: Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus Type 2- results of a pilot study. Exp. Clin. Endocrinol. Diabetes (2005) 113:49-52.
   Google Scholar
• SZAPARY PO, BLOEDON LT, SAMAHA FF et al.: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. (2006) 26:182-188.
   PubMed Web of Science ®Google Scholar
• PEREZ A, KHAN M, JOHNSON T, KARUNARATNE M: Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type diabetes. Diab. Vasc. Dis. Res. (2004) 1:44-50.
   PubMedGoogle Scholar
• GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. GLAI Study Investigators. Diabetes Care (2005) 28:1547-1554.
   PubMed Web of Science ®Google Scholar
• FLORKOWSKI CM: Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am. J. Cardiovasc. Drugs (2002) 2:15-21.
   PubMedGoogle Scholar
• HAYASHI T, HIRANO T, YAMAMOTO T, ITO Y, ADACHI M: Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with Type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism (2006) 55:879-884.
   Google Scholar
• CHU NV, KONG AP, KIM DD et al.: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care (2002) 25:542-549.
   PubMed Web of Science ®Google Scholar
• INOUE I, SHINODA Y, NAKANO T et al.: Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism (2006) 55:946-952.
   PubMed Web of Science ®Google Scholar